Variable |
Wild-type SARS-CoV-2 convalescents |
Unvaccinated Omicron convalescents |
Vaccinated Omicron
convalescents |
Number of participants |
20 |
5 |
27 |
Age (years), median
(range) |
53 (17-79) |
40 (34-43) |
29 (25-54) |
Sex at birth, female |
10 (50%) |
3 (60%) |
19
(70%) |
COVID vaccination history |
|
|
|
Two-dose inactivated vaccines |
0 |
N/A |
1 (3.7%) |
Three-dose inactivated vaccines |
0 |
N/A |
18 (66.7%) |
Two-dose Ad5-nCoV (adenovirus vector vaccine)
|
0
|
N/A
|
6 (22.2%)
|
Three-dose Recombinant Fusion Protein vaccines
|
0
|
N/A
|
1 (3.7%)
|
Two-dose inactivated vaccines plus one-dose Ad5-nCoV
|
0
|
N/A
|
1 (3.7%)
|
COVID disease severity |
|
|
|
Asymptomatic |
0 |
1 (20%) |
0 |
Mild |
4 (20%) |
4 (80%) |
19 (70%) |
Moderate |
9 (45%) |
0 |
8 (30%) |
Severe |
4 (20%) |
0 |
0 |
Critical |
3 (15%) |
0 |
0 |
Time between last vaccination and confirmed infection |
N/A |
N/A |
6-22 months |
Time between infection and serum sampling when SARS-CoV-2
negative |
2-8 weeks |
3-5 weeks |
2-9 weeks |
Method of SARS-CoV-2 testing |
|
|
|
Quantitative PCR |
20 (100%) |
1 (20%) |
5 (19%) |
Rapid antigen detection |
0 |
4 (80%) |
22 (81%) |